PMID- 32429902
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 19
TI  - Serum Fetuin-A levels are increased and associated with insulin resistance in 
      women with polycystic ovary syndrome.
PG  - 67
LID - 10.1186/s12902-020-0538-1 [doi]
LID - 67
AB  - BACKGROUND: Insulin resistance (IR) is a common characteristic of women with 
      polycystic ovary syndrome (PCOS). It has been reported that circulating Fetuin-A 
      levels were associated with IR and type 2 diabetes mellitus (T2DM). However, 
      previous reports were inconsistent. METHODS: Two hundred seven subjects were 
      screened for PCOS according to the diagnostic guideline of the Rotterdam 
      consensus criterion. Serum Fetuin-A levels were measured using an ELISA kit. An 
      independent t-test or Nonparametric test was used to detect differences between 
      PCOS and control groups. Spearman's correlation analysis was used to examine the 
      association of the serum Fetuin-A with other parameters. RESULTS: Our findings 
      showed that circulating Fetuin-A concentration ranged from 196.6 to 418.2 mug/L 
      for most women without PCOS (95%). Women with PCOS had higher circulating 
      Fetuin-A levels than healthy women (437.9 +/- 119.3 vs. 313.8 +/- 60.5 mug/L; 
      p <  0.01). Serum Fetuin-A was positively correlated with BMI, WHR, TG, TC, 
      LDL-C, HOMA-IR, LH, T, and DHEA-S. Multivariate regression analysis showed that 
      WHR, TG, HOMA-IR, and DHEA-S were independent predictors of the levels of 
      circulating Fetuin-A. Binary logistic regression revealed that serum Fetuin-A was 
      associated with the occurrence of PCOS. In addition, our ROC curve analysis found 
      that the cutoff values for Fetuin-A to predict PCOS and IR were 366.3 and 
      412.6 mug/L. CONCLUSION: Blood Fetuin-A may be a useful biomarker for screening 
      women for PCOS and IR.
FAU - Liu, Sha
AU  - Liu S
AD  - Department of Endocrinology, the Affiliated Hospital, Zunyi Medical University, 
      Zunyi, 563003, Guizhou, China.
FAU - Hu, Wenjing
AU  - Hu W
AD  - Chongqing Prevention and Treatment Hospital for Occupational Diseases, Chongqing, 
      China.
FAU - He, Yirui
AU  - He Y
AD  - Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical 
      University, Chongqing, China.
FAU - Li, Ling
AU  - Li L
AD  - Key Laboratory of Diagnostic Medicine (Ministry of Education) and Department of 
      Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical 
      University, Chongqing, 400016, China.
FAU - Liu, Hua
AU  - Liu H
AD  - Department of Pediatrics, University of Mississippi Medical Center, 2500 North 
      State Street, Jackson, MS, USA.
FAU - Gao, Lin
AU  - Gao L
AD  - Department of Endocrinology, the Affiliated Hospital, Zunyi Medical University, 
      Zunyi, 563003, Guizhou, China.
FAU - Yang, Gangyi
AU  - Yang G
AD  - Department of Endocrinology, the Affiliated Hospital, Zunyi Medical University, 
      Zunyi, 563003, Guizhou, China. gangyiyang@163.com.
AD  - Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical 
      University, Chongqing, China. gangyiyang@163.com.
FAU - Liao, Xin
AU  - Liao X
AD  - Department of Endocrinology, the Affiliated Hospital, Zunyi Medical University, 
      Zunyi, 563003, Guizhou, China. liaoxin8618@163.com.
LA  - eng
GR  - 81601214/the National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (AHSG protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (alpha-2-HS-Glycoprotein)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Insulin Resistance/*physiology
MH  - Polycystic Ovary Syndrome/*blood/*diagnosis
MH  - Young Adult
MH  - alpha-2-HS-Glycoprotein/*metabolism
PMC - PMC7236448
OTO - NOTNLM
OT  - Fetuin-a
OT  - Insulin resistance
OT  - Polycystic ovary syndrome
COIS- No potential conflicts of interest relevant to this article were reported.
EDAT- 2020/05/21 06:00
MHDA- 2021/03/16 06:00
PMCR- 2020/05/19
CRDT- 2020/05/21 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/05/19 00:00 [pmc-release]
AID - 10.1186/s12902-020-0538-1 [pii]
AID - 538 [pii]
AID - 10.1186/s12902-020-0538-1 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2020 May 19;20(1):67. doi: 10.1186/s12902-020-0538-1.